Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14820MR)

This product GTTS-WQ14820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11439MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ14334MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ7278MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ12424MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ5075MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ11640MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ13700MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW